Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,779
  • Shares Outstanding, K 47,898
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,600 K
  • 60-Month Beta -0.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.29
Trade GNPX with:

Options Overview Details

View History
  • Implied Volatility 134.50% ( -53.49%)
  • Historical Volatility 78.05%
  • IV Percentile 32%
  • IV Rank 9.82%
  • IV High 737.25% on 07/20/22
  • IV Low 68.89% on 09/10/21
  • Put/Call Vol Ratio 0.08
  • Today's Volume 1,664
  • Volume Avg (30-Day) 261
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 17,816
  • Open Int (30-Day) 16,887

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +60.77%
on 08/01/22
2.1600 -3.24%
on 08/15/22
+0.6500 (+45.14%)
since 07/15/22
3-Month
1.2900 +62.24%
on 06/17/22
2.1600 -3.24%
on 08/15/22
+0.5700 (+37.50%)
since 05/13/22
52-Week
1.1700 +78.63%
on 12/30/21
3.6200 -42.27%
on 01/03/22
-0.6700 (-24.28%)
since 08/13/21

Most Recent Stories

More News
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 2.0900 (+18.08%)
Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

GNPX : 2.0900 (+18.08%)
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 2.0900 (+18.08%)
Genprex to Participate in Upcoming Investor Conference in March

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 2.0900 (+18.08%)
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 2.0900 (+18.08%)
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 2.0900 (+18.08%)
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 2.0900 (+18.08%)
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 2.0900 (+18.08%)
Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

AZN : 66.81 (+0.26%)
MRK : 90.60 (-0.46%)
VTVT : 1.3700 (+6.20%)
GNPX : 2.0900 (+18.08%)
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 2.0900 (+18.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 2.6100
2nd Resistance Point 2.3800
1st Resistance Point 2.2400
Last Price 2.0900
1st Support Level 1.8700
2nd Support Level 1.6400
3rd Support Level 1.5000

See More

52-Week High 3.6200
Fibonacci 61.8% 2.6800
Fibonacci 50% 2.3900
Fibonacci 38.2% 2.1100
Last Price 2.0900
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar